TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25404752

Group type: EXPERIMENTAL
Intervention: Continuous endurance training (n=20): 33 min at 65-85% peak heart rate
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (n=20): 4 × 4 min intervals at 85-95% peak heart rate, followed by 3 min of active recovery at 60-70% peak heart rate
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pyramid training (n=20): 3 × 8 min of stepwise load increase and decrease from 65-95-65% peak heart rate, with 2 min recovery at 60-70% peak heart rate
Number of subjects: 60
Study: 24651814

Group type: EXPERIMENTAL
Intervention: Presence of leptomeningeal collaterals
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Dilation of the anterior choroidal artery
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Posterior communicating artery/ICA ratio
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Presence of infarct or hemorrhage
Number of subjects: 39

Group type: COMPARATOR
Intervention: Posterior communicating artery/ICA ratio and leptomeningeal collaterals
Number of subjects: 39
Study: 23115621

Group type: COMPARATOR
Intervention: Quadrivalent HPV vaccine (Gardasil™) - Dose 1
Number of subjects: 404
Study: 20956076

Group type: EXPERIMENTAL
Intervention: Registered FSWs
Number of subjects: 187

Group type: COMPARATOR
Intervention: Unregistered FSWs
Number of subjects: 187
Study: 17388666

Group type: EXPERIMENTAL
Intervention: Integrated peer education, free condom distribution, and syndromic STI management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Males attending program meetings
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Male STI patients in intervention communities
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control communities
Number of subjects: 0
Study: 15381923

Group type: EXPERIMENTAL
Intervention: RGS4 polymorphisms in first episode schizophrenia patients
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control subjects without RGS4 polymorphisms
Number of subjects: 57
Study: 12160194

Group type: EXPERIMENTAL
Intervention: Eplerenone 50 mg once daily
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Eplerenone 100 mg once daily
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Eplerenone 400 mg once daily
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Eplerenone 25 mg twice daily
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Eplerenone 50 mg twice daily
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Eplerenone 200 mg twice daily
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Spironolactone 50 mg twice daily
Number of subjects: 409

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 409
Study: 10466981

Group type: EXPERIMENTAL
Intervention: Combined therapy (ivermectin and albendazole)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ivermectin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Albendazole
Number of subjects: 0
Study: 7838545

Group type: EXPERIMENTAL
Intervention: Fibrin tissue adhesive applied to one side of the nasal cavity
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control side with packing coated with bacitracin
Number of subjects: 12
Study: 2090474

Group type: COMPARATOR
Intervention: Maintenance Dose (MD)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Twice the Maintenance Dose (MDx2)
Number of subjects: 32
Study: 6444958

Group type: EXPERIMENTAL
Intervention: 2% erythromycin
Number of subjects: 348

Group type: COMPARATOR
Intervention: vehicle (alcohol/propylene glycol)
Number of subjects: 348
Study: 31165191

Group type: EXPERIMENTAL
Intervention: Burosumab 1 mg/kg every 4 weeks
Number of subjects: 134

Group type: COMPARATOR
Intervention: Burosumab after placebo
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Burosumab
Number of subjects: 134
Study: 26198645

Group type: EXPERIMENTAL
Intervention: Comorbid BPD with MST-related PTSD
Number of subjects: 90

Group type: COMPARATOR
Intervention: Veterans without comorbid BPD
Number of subjects: 90
Study: 25790233

Group type: EXPERIMENTAL
Intervention: 100 mg rectal indomethacin
Number of subjects: 539

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 539
Study: 23554113

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg once daily for 5 days
Number of subjects: 374

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 374
Study: 21134775

Group type: EXPERIMENTAL
Intervention: Linezolid (IV or oral)
Number of subjects: 1056

Group type: COMPARATOR
Intervention: Vancomycin (IV)
Number of subjects: 1056
Study: 19136101

Group type: EXPERIMENTAL
Intervention: 1 injection of bupivacaine and triamcinolone
Number of subjects: 50

Group type: COMPARATOR
Intervention: 2 injections of bupivacaine and triamcinolone
Number of subjects: 50
Study: 18978166

Group type: EXPERIMENTAL
Intervention: Muesli with 4 g oat beta-glucan
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cornflakes meal
Number of subjects: 12
Study: 16291063

Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Standard moist wound care
Number of subjects: 162
Study: 12016603

Group type: EXPERIMENTAL
Intervention: EMLA (2.5% lidocaine and 2.5% prilocaine)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 4% amethocaine (4% AMET)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: AMLI (2.5% amethocaine and 2.5% lidocaine)
Number of subjects: 300
Study: 10465130

Group type: EXPERIMENTAL
Intervention: Cefepime monotherapy
Number of subjects: 69

Group type: COMPARATOR
Intervention: Combination therapy with trimethoprim/sulfamethoxazole plus amikacin (TMP/SMZ plus AMI)
Number of subjects: 69
Study: 8556967

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Imipramine (nasal users)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo (nasal users)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Imipramine (depressed users)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo (depressed users)
Number of subjects: 113
Study: 1697490

Group type: EXPERIMENTAL
Intervention: Cimetidine 1 g/day for 4 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vitamin C 1 g/day for 4 weeks
Number of subjects: 60
Study: 1107506

Group type: EXPERIMENTAL
Intervention: 0.1 mg/m2 of synthetic luteinizing hormone‐releasing hormone
Number of subjects: 20
Study: 31711990

Group type: COMPARATOR
Intervention: Active aspiration
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Gravity drainage
Number of subjects: 142
Study: 29056595

Group type: EXPERIMENTAL
Intervention: Contoured, prefabricated foot orthoses (n=153)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Flat insoles (control group, n=153)
Number of subjects: 306
Study: 28401667

Group type: EXPERIMENTAL
Intervention: Sleep restriction (3.5-4 hours in bed per night)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Habitual sleep (7-9 hours in bed per night)
Number of subjects: 43
Study: 26167716

Group type: EXPERIMENTAL
Intervention: Active marijuana (2.7-3.0% THC)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 23923440

Group type: EXPERIMENTAL
Intervention: Polyurethane foam (PU) applied in one extraction socket
Number of subjects: 10

Group type: COMPARATOR
Intervention: Commercially available gelatin foam applied in the other socket (gelatin group)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Collagen wadding applied in the other socket (collagen group)
Number of subjects: 10
Study: 21515226

Group type: EXPERIMENTAL
Intervention: 400 mg lumiracoxib
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 51
Study: 18070204

Group type: EXPERIMENTAL
Intervention: Topical application of 6% active complex antiageing cream
Number of subjects: 9

Group type: COMPARATOR
Intervention: Topical application of all-trans retinoic acid (RA)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Topical application of 2% active complex antiageing cream
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Topical application of basic moisturizer
Number of subjects: 9
Study: 16801738

Group type: EXPERIMENTAL
Intervention: Orlistat plus lifestyle management (OLM)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Wait-list control group (WLC)
Number of subjects: 107
Study: 12657858

Group type: EXPERIMENTAL
Intervention: 20 mg parecoxib sodium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 40 mg parecoxib sodium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11043842

Group type: EXPERIMENTAL
Intervention: Sodium clodronate 1600 mg daily p.o. (arm A)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo (arm B)
Number of subjects: 73
Study: 8842890

Group type: EXPERIMENTAL
Intervention: Community organization strategies including local physician planning groups, informational mailings, medical office staff training sessions, and reminder system support.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control communities (no specific intervention mentioned).
Number of subjects: 0
Study: 1735269

Group type: EXPERIMENTAL
Intervention: Allergen (Ag) inhalation
Number of subjects: 10
Study: 6733511

Group type: EXPERIMENTAL
Intervention: Uniform radiant heat stimuli of 18 s duration, raising skin surface temperature by 6 degrees C to a painful level (41‐43 degrees C) at interstimulus intervals of 35 s, 70 s, and 105 s.
Number of subjects: 7
Study: 30915650

Group type: EXPERIMENTAL
Intervention: Intravenous tocilizumab
Number of subjects: 132

Group type: COMPARATOR
Intervention: Intravenous abatacept
Number of subjects: 132
Study: 29590118

Group type: EXPERIMENTAL
Intervention: Periconceptional BMI change in Q1 (<-2.1 kg/m2)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Periconceptional BMI change in Q2 (-2.1 to -0.9 kg/m2)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Periconceptional BMI change in Q3 (-0.9 to 0.1 kg/m2)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Combined Q1 to Q3
Number of subjects: 321

Group type: COMPARATOR
Intervention: Control group (Q4, gained ≥0.1 kg/m2)
Number of subjects: 321
Study: 26675766

Group type: EXPERIMENTAL
Intervention: Sensitivity analysis in randomized controlled trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proposed 8-step strategy for conducting sensitivity analyses
Number of subjects: 0
Study: 24531843

Group type: EXPERIMENTAL
Intervention: Swimmer's position (SWIM)
Number of subjects: 380

Group type: COMPARATOR
Intervention: Standard position (STD)
Number of subjects: 380
Study: 19202154

Group type: EXPERIMENTAL
Intervention: Routine invasive strategy
Number of subjects: 184

Group type: COMPARATOR
Intervention: Selective invasive strategy
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Routine invasive strategy (meta-analysis)
Number of subjects: 184
Study: 20391869

Group type: EXPERIMENTAL
Intervention: Nonviolence training
Number of subjects: 58

Group type: COMPARATOR
Intervention: Untrained comparison group
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Nonviolence instruction
Number of subjects: 58
Study: 18622283

Group type: EXPERIMENTAL
Intervention: Reduced TAC (target trough level 3.0‐5.9 ng/mL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard TAC (target trough level 6.0‐8.9 ng/mL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total and low-density lipoprotein cholesterol in both TAC groups
Number of subjects: 0

Group type: COMPARATOR
Intervention: All TAC groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TAC-treated patients
Number of subjects: 0
Study: 16324598

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (2 months, resistive load of 40% of PImax)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 35
Study: 11833837

Group type: EXPERIMENTAL
Intervention: Humalog Mix75/25
Number of subjects: 143

Group type: COMPARATOR
Intervention: Glyburide 15 mg/d
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Humalog Mix75/25 (preprandial)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Humalog Mix75/25 (postprandial)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Glyburide
Number of subjects: 143
Study: 10050115

Group type: EXPERIMENTAL
Intervention: Porcelite dual-cure cement
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dual dual-cure cement
Number of subjects: 60

Group type: COMPARATOR
Intervention: C&B luting composite (chemically activated cement)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All cements tested at 7 days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dual-cure cements at 90 minutes
Number of subjects: 60
Study: 7718549

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (CaCO3 tablet, 300 mg Ca)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Comparison of individual changes in TFCA
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Differential in TFCA between groups after 6 months
Number of subjects: 34
Study: 2202200

Group type: EXPERIMENTAL
Intervention: Sucralfate (3 g/day)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Sulglycotide (600 mg/day)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control (Helicobacter pylori colonization)
Number of subjects: 89
Study: 7056270

Group type: EXPERIMENTAL
Intervention: Spironolactone 100mg b.i.d.
Number of subjects: 8

Group type: COMPARATOR
Intervention: Digoxin
Number of subjects: 8
Study: 31378665

Group type: EXPERIMENTAL
Intervention: Metabolomic profile based on fatty acid metabolism and γ‐glutamyl amino acids
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Metabolic risk score based on four metabolites
Number of subjects: 347

Group type: COMPARATOR
Intervention: No specific intervention
Number of subjects: 347
Study: 30170823

Group type: EXPERIMENTAL
Intervention: Healthy Weight Counseling MOC program
Number of subjects: 102
Study: 28987767

Group type: EXPERIMENTAL
Intervention: High-heeled footwear (7-11cm)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Standard control shoes
Number of subjects: 37
Study: 26994089

Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted lopinavir (400/100 mg) with tenofovir disoproxil/emtricitabine (245/200 mg)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Raltegravir (400 mg) with tenofovir disoproxil/emtricitabine (245/200 mg)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted lopinavir (400/100 mg)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Raltegravir (400 mg)
Number of subjects: 243
Study: 25069759

Group type: EXPERIMENTAL
Intervention: IFN α‐2b therapy for ET patients with JAK2V617F(+).
Number of subjects: 259

Group type: COMPARATOR
Intervention: IFN α‐2b therapy for PV patients with JAK2V617F(+).
Number of subjects: 259

Group type: COMPARATOR
Intervention: IFN α‐2b therapy for MPDs patients.
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: IFN α‐2b therapy.
Number of subjects: 259
Study: 22140200

Group type: EXPERIMENTAL
Intervention: Immediate group (2 hours of inpatient physical and occupational therapy focusing on coordination, balance, and ADLs for 4 weeks)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Immediate group
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (received the same intervention after a 4-week delay)
Number of subjects: 42
Study: 20415302

Group type: EXPERIMENTAL
Intervention: Ultrasonography-guided suprascapular nerve block
Number of subjects: 50

Group type: COMPARATOR
Intervention: Blind suprascapular nerve block (control)
Number of subjects: 50
Study: 17934240

Group type: EXPERIMENTAL
Intervention: Royal jelly (RJ) supplementation at 6 g per day for 4 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Royal jelly (RJ) supplementation
Number of subjects: 15
Study: 15986287

Group type: EXPERIMENTAL
Intervention: Evaluation for dyspepsia prior to elective heart surgery
Number of subjects: 894

Group type: EXPERIMENTAL
Intervention: Active peptic ulcer with stigmata of recent bleeding
Number of subjects: 894

Group type: EXPERIMENTAL
Intervention: H. pylori infection
Number of subjects: 894
Study: 11932277

Group type: EXPERIMENTAL
Intervention: Levothyroxine treatment
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49

Group type: COMPARATOR
Intervention: Subclinical hypothyroidism (SCH) patients compared to controls
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Subclinical hypothyroidism (SCH) patients
Number of subjects: 49
Study: 9866411

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Open cholecystectomy
Number of subjects: 60
Study: 7615227

Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg per OS three times during the day before the procedure and one 10‐mg dose on the morning of the procedure)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo (identical appearance to cisapride)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Cisapride and Placebo
Number of subjects: 84
Study: 2116160

Group type: EXPERIMENTAL
Intervention: Atenolol (4 mg i.v.)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Buccal nitroglycerin (5 mg)
Number of subjects: 30
Study: 755871

Group type: EXPERIMENTAL
Intervention: Feedback condition with auditory signal correlated with EMG responses
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control condition with constant low tone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Yoked-incentive subjects in control condition
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: No-incentive subjects in control condition
Number of subjects: 100
Study: 31356561

Group type: EXPERIMENTAL
Intervention: Propofol at 480 mg/min (group A)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Propofol at 240 mg/min (group B)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Propofol at 120 mg/min (group C)
Number of subjects: 90
Study: 27794195

Group type: EXPERIMENTAL
Intervention: Dual task cognitive rehabilitation program (n-back test and PFM exercises)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no specific instructions, no PFM exercises)
Number of subjects: 39
Study: 26062881

Group type: EXPERIMENTAL
Intervention: Dual treatment with atazanavir (300 mg once daily) and ritonavir (100 mg once daily) plus lamivudine (300 mg once daily)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Triple treatment with atazanavir (300 mg once daily) and ritonavir (100 mg once daily) plus two nucleos(t)ide reverse transcriptase inhibitors
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Dual treatment
Number of subjects: 286

Group type: COMPARATOR
Intervention: Triple treatment
Number of subjects: 286
Study: 23748233

Group type: EXPERIMENTAL
Intervention: Systematic provision of printed information about psychosocial support services
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (no systematic information)
Number of subjects: 108
Study: 21747351

Group type: EXPERIMENTAL
Intervention: 980 nm diode laser
Number of subjects: 180

Group type: COMPARATOR
Intervention: 1500 nm diode laser
Number of subjects: 180
Study: 19250085

Group type: EXPERIMENTAL
Intervention: Robotic navigation for catheter ablation
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conventional hand-controlled catheter ablation
Number of subjects: 38
Study: 16415894

Group type: COMPARATOR
Intervention: ATG (Thymoglobulin 2 mg/kg x 3 days)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Campath (30 mg x 3 days subcutaneously)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Campath (30 mg once)
Number of subjects: 69
Study: 14760948

Group type: EXPERIMENTAL
Intervention: IFN‐beta+GA
Number of subjects: 19

Group type: COMPARATOR
Intervention: IFN‐beta alone
Number of subjects: 19

Group type: COMPARATOR
Intervention: Untreated MS
Number of subjects: 19

Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 19
Study: 11369502

Group type: EXPERIMENTAL
Intervention: alpha-tocopherol (400 IU dL-alpha-tocopherol daily)
Number of subjects: 128

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: alpha-tocopherol
Number of subjects: 128
Study: 10717770

Group type: EXPERIMENTAL
Intervention: Natural light/dark cycle (L/Dc) exposure through windows
Number of subjects: 24

Group type: COMPARATOR
Intervention: No daylight exposure, but access to normal clock time
Number of subjects: 24
Study: 8858272

Group type: EXPERIMENTAL
Intervention: Clonidine (0.1 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Yohimbine (5.4 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 1517383

Group type: EXPERIMENTAL
Intervention: tiratricol 10 micrograms/kg
Number of subjects: 10
Study: 6343022

Group type: EXPERIMENTAL
Intervention: Progressive relaxation training for 5 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no relaxation training)
Number of subjects: 12
Study: 31955491

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 76

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 76
Study: 29553804

Group type: EXPERIMENTAL
Intervention: Savoring life lessons
Number of subjects: 303

Group type: COMPARATOR
Intervention: Reflecting on negative aspects of aging
Number of subjects: 303

Group type: COMPARATOR
Intervention: Untreated-control condition
Number of subjects: 303
Study: 29794738

Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT) - 3 sessions/week for 12 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Mindfulness Training (MT) - 1 session/week for 8 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both AT and MT
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 40
Study: 26536339

Group type: EXPERIMENTAL
Intervention: High-environmental fidelity simulation (HF(en)S)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Low-environmental fidelity simulations (LF(en)S)
Number of subjects: 39
Study: 25005057

Group type: EXPERIMENTAL
Intervention: Extra-abdominal repair (group 1)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: In situ repair (group 2)
Number of subjects: 1000